Buprenorphine

Major

Buprenorphine Thioridazine Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine, an increased risk of QT interval prolongation, an increased ris... Details Buprenorphine Thiothixene Explained Increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Tianeptine Explained An increased risk of serotonin syndrome Details Buprenorphine Ticagrelor Brilinta Explained Reduced absorption of ticagrelor Details Buprenorphine Tilidine Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Tiotropium Explained An increased risk of paralytic ileus Details Buprenorphine Tizanidine Explained Enhanced neuromuscular blocking action, an increased risk of respiratory depression and CNS depression and an increased risk of pa... Details Buprenorphine Tolonium Chloride Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Tolterodine Detrol Explained An increased risk of paralytic ileus and an increased risk of QT interval prolongation Details Buprenorphine Topiramate Eprontia Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Toremifene Fareston Explained An increased risk of QT interval prolongation Details Buprenorphine Torsemide Soaanz Explained Reduced efficacy of diuretics Details Buprenorphine Tramadol ConZip Explained Reduced efficacy of traMADol, an increased risk of withdrawal symptoms, an increased risk of serotonin syndrome and an increased r... Details Buprenorphine Trazodone Raldesy Explained Increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of CNS depression Details Buprenorphine Triamterene Dyrenium Explained Reduced efficacy of diuretics Details Buprenorphine Triazolam Halcion Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Trichlormethiazide Explained Reduced efficacy of diuretics Details Buprenorphine Triclabendazole Egaten Explained An increased risk of QT interval prolongation Details Buprenorphine Trifluoperazine Explained An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Trifluperidol Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Triflupromazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Trihexyphenidyl Explained An increased risk of paralytic ileus Details Buprenorphine Trimeprazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Trimipramine Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Triptorelin Explained An increased risk of QT interval prolongation Details Buprenorphine Troleandomycin Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Tropicamide Mydriacyl Explained An increased risk of paralytic ileus Details Buprenorphine Trospium Explained An increased risk of paralytic ileus Details Buprenorphine Tryptophan Explained An increased risk of serotonin syndrome Details Buprenorphine Tucatinib Tukysa Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Umeclidinium Explained An increased risk of paralytic ileus Details Buprenorphine Vandetanib Caprelsa Explained An increased risk of QT interval prolongation Details Buprenorphine Vardenafil Levitra Explained An increased risk of QT interval prolongation Details Buprenorphine Vemurafenib Zelboraf Explained An increased risk of QT interval prolongation Details Buprenorphine Venlafaxine Explained An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Vepdegestrant Veppanu Explained An increased risk of QT interval prolongation and an increased risk of torsade de pointes, polymorphic ventricular tachycardia, ot... Details Buprenorphine Verapamil Calan Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Vilanterol Explained An increased risk of QT interval prolongation Details Buprenorphine Vilazodone Viibryd Explained An increased risk of serotonin syndrome Details Buprenorphine Vinflunine Explained An increased risk of QT interval prolongation Details